Added by PPMD on November 18, 2014 at 1:28pm — No Comments
At the Action Duchenne meeting in London on Saturday, Pfizer Inc. announced that it has completed a study in healthy volunteers with its antibody-based therapeutic to block the muscle protein myostatin, and is preparing to start recruitment for a phase II study in Duchenne this month. Watch…Continue
Added by PPMD on November 14, 2014 at 12:59pm — No Comments
The FDA is listening and has told us as much. But that doesn’t mean we should stop doing everything we can to educate the Agency.
Thanks to the dozens of you who participated in PPMD’s benefit/risk project and took the time to share your story, we have been able to compile your responses and will be providing the FDA with…Continue